Federation des caisses Desjardins du Quebec Sells 4,858 Shares of Becton, Dickinson and Company $BDX

Key Points

• The Federation des caisses Desjardins du Quebec reduced its holdings in Becton, Dickinson and Company by 7%, selling 4,858 shares in the first quarter.
• Despite the sale, other major investors such as Vanguard Group and T. Rowe Price increased their stakes in Becton, Dickinson, indicating continued institutional interest in the company.
• Becton, Dickinson recently announced a quarterly dividend of $1.04, reflecting a 2.2% yield and a payout ratio of approximately 74.82%.

Federation des caisses Desjardins du Quebec lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,173 shares of the medical instruments supplier's stock after selling 4,858 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in Becton, Dickinson and Company were worth $14,706,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Saudi Central Bank purchased a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth about $27,000. REAP Financial Group LLC boosted its position in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Cornerstone Planning Group LLC boosted its position in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $0.92 during trading on Friday, hitting $192.18. The company's stock had a trading volume of 1,244,193 shares, compared to its average volume of 2,050,719. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average price of $185.08 and a 200 day moving average price of $192.84. The firm has a market cap of $55.08 billion, a P/E ratio of 34.56, a price-to-earnings-growth ratio of 1.44 and a beta of 0.27. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter last year, the firm earned $3.50 EPS. Becton, Dickinson and Company's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 863 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the sale, the director owned 23,143 shares of the company's stock, valued at $4,450,398.90. The trade was a 3.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Barclays cut their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Piper Sandler reissued a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.